Key Highlights
- SkinBioTherapeutics (LSE:SBTX) shares closed at 6.00p on 16 October 2026, up 4.35%, returning to the level reached after an early-week rally.
- On 13 October the AIM-listed stock jumped 11.1% to 6.00p after the company issued a pre-close trading update for the year ended 30 June 2026.
- Revenue for FY26 is expected to have grown by approximately 20.5% to about £4.7 million, compared with a restated £3.9 million a year earlier.
- The board confirmed that the interim chief executive and acting chair will take on their roles on a permanent basis, ending a period of leadership uncertainty.
- Investors remain focused on cash, as growth in contract manufacturing revenue has come alongside a lower cash balance.
Why SkinBioTherapeutics Is Trending on 16 October 2026
SkinBioTherapeutics plc (LSE:SBTX) was again among the AIM healthcare names drawing attention on Friday 16 October 2026, as its shares finished the session at 6.00p, a rise of 4.35% on the day. The move followed a strong start to the week. On Monday 13 October, the shares climbed 11.1% to 6.00p after the life sciences group released a pre-close trading update for its 2026 financial year and confirmed changes to its leadership structure.
The combination of double-digit revenue growth and a settled boardroom appears to have improved sentiment towards a company that has spent much of the past year rebuilding investor confidence. Friday's gain took the shares back to the level reached on Monday after some midweek easing, suggesting buyers were willing to step in again rather than let the earlier rally fade.
Inside the FY26 Trading Update
In its trading statement, SkinBioTherapeutics said it expects revenue for the twelve months to 30 June 2026 to be approximately £4.7 million. That represents growth of around 20.5% on the prior year, whose comparable figure of £3.9 million has been restated. The company attributed the improvement largely to a full year of trading from businesses added to the group, with contract manufacturing playing an important role in lifting sales.
The update was a pre-close statement rather than audited results, so the final figures, along with profit, loss and cash flow detail, will be confirmed when full-year accounts are published. Even so, the direction of travel is encouraging for a small company that has been working to convert its scientific platform into a sustainable revenue base.
Leadership Made Permanent
Alongside the financial update, SkinBioTherapeutics (LSE:SBTX) confirmed that its interim chief executive and its acting chair have been appointed to their roles permanently. Leadership changes had been a source of uncertainty for shareholders, particularly after the company went through a difficult period that included a restatement of its earlier financial results. Removing the interim labels gives the board and management team a clearer mandate to execute strategy, and gives investors greater visibility on who is accountable for delivering growth and financial discipline.
Business Background
SkinBioTherapeutics is a life sciences company focused on the human microbiome, the community of microorganisms that live on and in the body. Its research platform centres on identifying the health benefits that bacteria and their derivatives can bring to the skin and gut. Over time, the group has broadened from early-stage research into commercial activity, including consumer health products and contract manufacturing services. The manufacturing side provides recurring revenue that helps fund research and development and reduces the company's reliance on licensing deals that can take years to materialise.
Financial Position and Cash
While top-line growth is welcome, the company's balance sheet remains the key question for investors in SkinBioTherapeutics plc (LSE:SBTX). The FY26 picture shows revenue rising through contract manufacturing while the group's cash position fell over the year. For a small-cap company with a share price in single-digit pence, that trend matters, because any shortfall in funding may need to be filled through new equity, which could dilute existing shareholders. The company's half-year report for 2026 also included restated figures for FY25, underlining the importance of the upcoming audited accounts in giving the market a clean and reliable base to work from.
Sector and Market Context
The microbiome space has attracted strong scientific interest, but commercial progress across the sector has been uneven. Many companies have found that clinical development costs are high and that partnerships with larger consumer health or pharmaceutical groups take time to agree. Against that backdrop, smaller businesses that can generate revenue from manufacturing or consumer products are often viewed more favourably than pure research plays. UK small-cap healthcare stocks have also been sensitive to wider risk appetite, interest rate expectations and funding conditions on AIM, which can amplify share price moves in either direction.
Risks to Consider
Investors should weigh several risks. Cash burn and funding needs remain the most immediate concern, given the decline in cash reported during FY26. The earlier restatement of results means governance and financial controls will continue to be scrutinised. Revenue concentration in contract manufacturing could leave the company exposed if key customers reduce orders. Thin trading on AIM can also cause sharp swings.
What Investors Are Watching Next
The next major milestone for SkinBioTherapeutics (LSE:SBTX) is the publication of audited full-year results, which should confirm FY26 revenue and set out losses, cash and the funding runway in detail. Shareholders will also look for the permanent leadership team to outline its priorities, including plans for margin improvement, cost control and the commercial use of the microbiome research platform.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...